In December, the United States Patent Trial and Appeal Board heard oral arguments in what will prove to be one of the most important patent disputes of the decade. At stake is intellectual property rights to one of the most potentially lucrative scientific developments in recent memory, CRISPR-based genome editing. But for many scientists, the case is less about that than it is about the clash of two scientific cultures, one driven by pure inquiry and another driven by economic motives.
Read Full Article »
